lutetium-lu-177-dotatate and Thymoma

lutetium-lu-177-dotatate has been researched along with Thymoma* in 1 studies

Other Studies

1 other study(ies) available for lutetium-lu-177-dotatate and Thymoma

Article	Year
Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT. Clinical nuclear medicine, 2015, Volume: 40, Issue:5 A 47-year-old man presented with a recurrent thymoma World Health Organization type A of the anterior chest wall with pleural metastases after failing chemotherapy. The tumor was positive on In-octreotide, and he was referred for peptide receptor radionuclide therapy (PRRT) with Lu DOTATATE. He received 4 induction and 2 maintenance Lu DOTATATE treatments (total dose, 1000 mCi) and reported significant improvement in symptoms. Before the seventh treatment, mild progression was diagnosed on CT, and PRRT was terminated. The use of induction and maintenance Lu DOTATATE PRRT therapy in the management of thymoma warrants further research. Topics: Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Thymoma	2015

Article

Year

Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.

Clinical nuclear medicine, 2015, Volume: 40, Issue:5

A 47-year-old man presented with a recurrent thymoma World Health Organization type A of the anterior chest wall with pleural metastases after failing chemotherapy. The tumor was positive on In-octreotide, and he was referred for peptide receptor radionuclide therapy (PRRT) with Lu DOTATATE. He received 4 induction and 2 maintenance Lu DOTATATE treatments (total dose, 1000 mCi) and reported significant improvement in symptoms. Before the seventh treatment, mild progression was diagnosed on CT, and PRRT was terminated. The use of induction and maintenance Lu DOTATATE PRRT therapy in the management of thymoma warrants further research.

Topics: Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Thymoma

2015